The National Institutes of Health (NIH) is offering a funding opportunity for the Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required), aimed at facilitating multi-site Phase Ib to III clinical trials focused on pharmacological and non-pharmacological interventions for Alzheimer's disease (AD) and related dementias. This initiative encourages applications from a diverse range of entities, including academic institutions and small businesses, to enhance scientific understanding and promote inclusivity in research populations. With an estimated funding allocation of approximately $10 million for FY 2025, interested applicants should note that the application submission period opens on September 16, 2024, and closes on October 18, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-010.html.